X4 Pharmaceuticals Inc. (XFOR)
X4 Pharmaceuticals Statistics
Share Statistics
X4 Pharmaceuticals has 170.55M shares outstanding. The number of shares has increased by 1.55% in one year.
| Shares Outstanding | 170.55M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.21% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 117.85M |
| Failed to Deliver (FTD) Shares | 50.01K |
| FTD / Avg. Volume | 1.29% |
Short Selling Information
The latest short interest is 11.42M, so 6.7% of the outstanding shares have been sold short.
| Short Interest | 11.42M |
| Short % of Shares Out | 6.7% |
| Short % of Float | 9.69% |
| Short Ratio (days to cover) | 8.64 |
Valuation Ratios
The PE ratio is -1.47 and the forward PE ratio is -0.87.
| PE Ratio | -1.47 |
| Forward PE | -0.87 |
| PS Ratio | 0 |
| Forward PS | 1.4 |
| PB Ratio | 2.92 |
| P/FCF Ratio | -1.54 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for X4 Pharmaceuticals Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.34, with a Debt / Equity ratio of 1.14.
| Current Ratio | 5.34 |
| Quick Ratio | 5.34 |
| Debt / Equity | 1.14 |
| Total Debt / Capitalization | 53.28 |
| Cash Flow / Debt | -1.66 |
| Interest Coverage | -18.61 |
Financial Efficiency
Return on equity (ROE) is -1.98% and return on capital (ROIC) is -98.38%.
| Return on Equity (ROE) | -1.98% |
| Return on Assets (ROA) | -0.69% |
| Return on Capital (ROIC) | -98.38% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -796.59K |
| Employee Count | 127 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 78.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -42.18% in the last 52 weeks. The beta is 0.39, so X4 Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.39 |
| 52-Week Price Change | -42.18% |
| 50-Day Moving Average | 0.53 |
| 200-Day Moving Average | 0.73 |
| Relative Strength Index (RSI) | 42.8 |
| Average Volume (20 Days) | 3.87M |
Income Statement
| Revenue | n/a |
| Gross Profit | -2.00M |
| Operating Income | -107.52M |
| Net Income | -101.17M |
| EBITDA | -107.10M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.57 |
Balance Sheet
The company has 99.22M in cash and 58.28M in debt, giving a net cash position of 40.94M.
| Cash & Cash Equivalents | 99.22M |
| Total Debt | 58.28M |
| Net Cash | 40.94M |
| Retained Earnings | -477.90M |
| Total Assets | 178.16M |
| Working Capital | 113.71M |
Cash Flow
In the last 12 months, operating cash flow was -96.51M and capital expenditures -60.00K, giving a free cash flow of -96.57M.
| Operating Cash Flow | -96.51M |
| Capital Expenditures | -60.00K |
| Free Cash Flow | -96.57M |
| FCF Per Share | -0.54 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
XFOR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -116.33% |
| FCF Yield | -115.51% |
Analyst Forecast
The average price target for XFOR is $4, which is 716.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $4 |
| Price Target Difference | 716.3% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Mar 14, 2019. It was a backward split with a ratio of 1:6.
| Last Split Date | Mar 14, 2019 |
| Split Type | backward |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | -5.04 |
| Piotroski F-Score | 2 |